Interventional × Cholangiocarcinoma × Other solid neoplasm × Clear all
NCT06336148 2025-10-15

A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors

Actym Therapeutics, Inc.

Phase 1 Terminated
10 enrolled
NCT02628067 2025-09-22

KEYNOTE 158

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting
1,609 enrolled 5 FDA
NCT05563272 2025-07-10

STARBURST

Telix Pharmaceuticals (Innovations) Pty Limited

Phase 2 Terminated
11 enrolled
NCT06638931 2025-05-28

ANTARES

Instituto do Cancer do Estado de São Paulo

Phase 2 Active not recruiting
28 enrolled
NCT05215574 2024-10-10

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

NGM Biopharmaceuticals, Inc

Phase 1 Active not recruiting
130 enrolled
NCT04913337 2024-10-02

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

NGM Biopharmaceuticals, Inc

Phase 1/2 Active not recruiting
179 enrolled
NCT05311618 2024-04-01

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

NGM Biopharmaceuticals, Inc

Phase 1 Active not recruiting
71 enrolled
NCT04430842 2023-01-18

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

Quadriga Biosciences, Inc.

Phase 1 Completed
15 enrolled
NCT03517488 2022-12-01

DUET-2

Xencor, Inc.

Phase 1 Completed
150 enrolled
NCT03071757 2022-04-28

A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

AbbVie

Phase 1 Completed
139 enrolled